All In Biotech

Drug Trial Radar · NCT05312710

Safety and Efficacy of APG-157 in Head and Neck Cancer

Phase 2 Study to Evaluate the Safety and Efficacy of APG-157 as Neoadjuvant/Induction Therapy for Patients With Head and Neck Squamous Cell Cancer (HNSCC) of the Oral Cavity and/or Oropharynx

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 22, 2022

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Aveta Biomics, Inc.Industry
Sponsor type
Industry
First posted
Apr 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the outcomes over current standard of care.

Conditions

  • Head and Neck Cancer
  • Squamous Cell Carcinoma of Oral Cavity
  • Squamous Cell Carcinoma of the Oropharynx

Interventions

  • APG-157Drug

    Treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Imaging to assess drug's ability to impact tumor sizeTime frame: Baseline to end of dosing is four weeks (extendable up to 6 weeks) of APG-157 dosing. Baseline is at time of diagnosis. End of dosing is day before surgery or start of other definitive therapy and/or radiation

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • VAGLAHS, West Los Angeles

    Los Angeles, California

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.